Почетна › Urotelni (prelaznoćelijski) karcinom › Њујорк › New York City
Kliničke studije za Urotelni (prelaznoćelijski) karcinom u gradu New York City, NY
22 studija za Urotelni (prelaznoćelijski) karcinom traži učesnike na lokacijama u gradu New York City i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Тражи се учесникФаза 2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Тражи се учесникФаза 2
- Memorial Sloan Kettering Cancer Center, New York
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Тражи се учесникФаза 3
- Icahn School of Medicine at Mount Sinai, New York
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Тражи се учесникФаза 1/2
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Тражи се учесникФаза 1
- New York Cancer & Blood Specialists, New York
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Тражи се учесникФаза 1/2
- Tisch Cancer Institute (TCI), Icahn School of Medicine, New York
- Columbia University, New York
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Тражи се учесникФаза 1/2
- Clinical Trial Site, New York
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Тражи се учесникФаза 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Тражи се учесникФаза 1
- MSK, New York
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Тражи се учесникФаза 1/2
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Icahn School of Medicine at Mount Sinai, New York
- Evelyn H. Lauder Breast and Imaging Center (BAIC), New York
- и још 2
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Тражи се учесникФаза 3
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medical College, New York
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Тражи се учесникФаза 1
- Exelixis Clinical Site #60, New York
- Exelixis Clinical Site #6, New York
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Тражи се учесникОпсервациона студија
- NYU Grossman School of Medicine, New York
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Тражи се учесникФаза 1
- Columbia University Irving Medical Center, New York
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
Тражи се учесникФаза 1
- Mount Sinai Hospital, New York
- NYP/Weill Cornell Medical Center, New York
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
Тражи се учесникФаза 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Тражи се учесникФаза 2
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Icahn School of Medicine at Mount Sinai, New York
- Evelyn H. Lauder Breast and Imaging Centre (BAIC), New York
- и још 2
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Тражи се учесникФаза 3
- Research Site, New York
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
Тражи се учесник
- Integrated Medical Professionals, New York
A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma
Тражи се учесникОпсервациона студија
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
Тражи се учесникФаза 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Тражи се учесникОпсервациона студија
- Massive Bio SYNERGY-AI site, New York
Studije za Urotelni (prelaznoćelijski) karcinom u drugim gradovima
- Nashville, TN24 студија
- Houston, TX20 студија
- Edison, NJ18 студија
- Dallas, TX18 студија
- Los Angeles, CA17 студија
- Queens, NY16 студија
- Chicago, IL14 студија
- Boston, MA13 студија
- Arlington, VA13 студија
- San Antonio, TX13 студија
- Austin, TX10 студија
- Orlando, FL10 студија
Ostale studije u gradu New York City
- Рак дојке144 студија
- Немалоклетни карцином плућа123 студија
- Рак (све врсте)105 студија
- Рак простате101 студија
- Метастатски карцином93 студија
- Колоректални карцином86 студија
- Рак јајника75 студија
- Рак плућа60 студија
- Многи мијелом59 студија
- Рак панкреаса57 студија
- Карцином ендометријума54 студија
- Akutna mijeloidna leukemija51 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.